Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071794 | 1.00 | PARP14 (0.72) | PARP14 | |
| SCHEMBL21072480 | 0.84 | PARP14 (0.92) | PARP14 | |
| SCHEMBL21072477 | 0.84 | PARP14 (1.00) | PARP14 | |
| SCHEMBL21072387 | 0.81 | PARP14 (1.00) | PARP14 | |
| SCHEMBL21072504 | 0.80 | PARP14 (1.00) | PARP14 | |
| SCHEMBL21072026 | 0.79 | PARP14 (0.69) | PARP14 | |
| SCHEMBL29602419 | 0.78 | PARP14 (0.73) | PARP14 | |
| SCHEMBL21071785 | 0.78 | PARP14 (1.00) | PARP14 | |
| SCHEMBL29443182 | 0.78 | PARP14 (1.00) | PARP14 | |
| Hydrochloric Acid SCHEMBL31451236 | 0.78 | PARP14 (0.72) | PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284376-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Ribon Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | claimed |
| WO-2022165118-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | RIBON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| CN-111699176-B | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4284376-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Ribon Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| WO-2022165118-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | RIBON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-3986887-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Ribon Therapeutics Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114206853-A | Targeted protein degradation of PARP14 for therapy | 里邦医疗公司 | 2022-03-18 | — | — | CN | disclosed |